Carla Cristina Perez

Carla Cristina Perez

Auto-generated profile, based on publicly available information

Carla Cristina Perez

Laboratório de Síntese de Moléculas Medicinais (LaSMMed), Departamento de Química, Centro de Ciências Exatas, Universidade Estadual de Londrina, Londrina, Brazil

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2010 in Chemistry & Biodiversity
Verified
Journal Article
Closed access
PDF file
ASAndré Gonzaga Dos Santos
André Gonzaga Dos Santos
PFPaulo Michel Pinheiro Ferreira
Paulo Michel Pinheiro Ferreira
GJGerardo Magela Vieira Junior
Gerardo Magela Vieira Junior
CPCarla Cristina Perez
Carla Cristina Perez
ATAristeu Gomes Tininis
Aristeu Gomes Tininis
ACAlberto José Cavalheiro
Alberto José Cavalheiro

1 October 2007 in Química Nova
Verified
Journal Article
Open access
PDF file
ASAndré Gonzaga Dos Santos
André Gonzaga Dos Santos
CPCarla C. Perez
Carla C. Perez
ATAristeu G. Tininis
Aristeu G. Tininis
VBVanderlan Bolzani
Vanderlan Bolzani
ACAlberto J. Cavalheiro
Alberto J. Cavalheiro
Ethanolic extracts of the leaves of Casearia sylvestris yielded a novel clerodane diterpene, 15-hydroxy-3-cleroden-2-one, together with the known diterpenes (-)-hardwickiic acid, reported for the first time from this species, and casearins B and G, previously isolated from C. sylvestris. The structures of all four compounds were determined by spectrometric analysis. The new clerodane diterpene and (-)-hardwickiic acid contain structural features that are completely different from the highly oxygenated casearins and casearvestrins isolated from C. sylvestris.

13 June 2014 in New Journal of Chemistry
Verified
Journal Article
Closed access
PDF file
CPCarla Cristina Perez
Carla Cristina Perez
JPJesus Marcelo Pena
Jesus Marcelo Pena
CCCarlos Roque Duarte Correia
Carlos Roque Duarte Correia
Design of experiments (DOE) was instrumental to optimize reaction conditions which allowed the efficient synthesis of key bioactive stilbenes.

3 November 2022 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
GGGabriel Felix da Silva Gomes
Gabriel Felix da Silva Gomes
PCPriscila Goes Camargo
Priscila Goes Camargo
KSKaio Maciel de Santiago-Silva
Kaio Maciel de Santiago-Silva
HSHelena Tiemi Suzukawa
Helena Tiemi Suzukawa
ARAna Paula Sotero da Silva Ribeiro
Ana Paula Sotero da Silva Ribeiro
CPCarla Cristina Perez
Carla Cristina Perez
COVID-19, a disease caused by SARS-CoV-2, was declared a pandemic in 2020 and created a global crisis in health systems, with more than 545 million confirmed cases and 6.33 million deaths. In this sense, this work aims to identify possible inhibitors of the SARS-CoV-2 RdRp enzyme using in silico approaches. RdRp is a crucial enzyme in the replication and assembly cycle of new viral particles and a critical pharmacological target in the treatment of COVID-19. We performed a virtual screening based on molecular docking from our in-house chemical library, which contains a diversity of 313 structures from different chemical classes. Nine compounds were selected since they showed important interactions with the active site from RdRp. Next, the ADME-Tox in silico predictions served as a filter and selected the three most promising compounds: a coumarin LMed-052, a hydantoin LMed-087, and a guanidine LMed-250. Molecular dynamics simulations revealed details such as changes in the positions of ligands and catalytic residues during the simulations compared to the complex from molecular docking studies. Binding free energy analysis was performed using the MMGBSA method, demonstrating that LMed-052 and LMed-087 have better affinities for the RdRp by energetic contributions to the stability of the complexes when compared to LMed-250. Furthermore, LMed-052 showed significant in vitro inhibition against MHV-3, decreasing 99% of viral titers. Finally, these findings are useful to guide structural modifications aiming to improve the potential of these compounds to act as inhibitors of SARS-CoV-2. Communicated by Ramaswamy H. Sarma

20 September 2022 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
KSKaio Maciel de Santiago-Silva
Kaio Maciel de Santiago-Silva
PCPriscila Goes Camargo
Priscila Goes Camargo
GGGabriel Felix da Silva Gomes
Gabriel Felix da Silva Gomes
ASAna Paula Sotero
Ana Paula Sotero
AOAlexandre Orsato
Alexandre Orsato
MBMarcelle de Lima Ferreira Bispo
Marcelle de Lima Ferreira Bispo
The coronavirus disease-2019 (COVID-19) pandemic, caused by the novel coronavirus severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), became the highest public health crisis nowadays. Although the use of approved vaccines for emergency immunization and the reuse of FDA-approved drugs remains at the forefront, the search for new, more selective, and potent drug candidates from synthetic compounds is also a viable alternative to combat this viral disease. In this context, the present study employed a computational virtual screening approach based on molecular docking and molecular dynamics (MD) simulation to identify possible inhibitors for SARS-CoV-2 Mpro (main protease), an important molecular target required for the maturation of the various polyproteins involved in viral replication. The virtual screening approach selected four potential inhibitors against SARS-CoV-2 Mpro. In addition, MD simulation studies revealed changes in the positions of the ligands during the simulations compared to the complex obtained in the molecular docking studies, showing the benzoylguanidines LMed-110 and LMed-136 have a higher affinity for the active site compared to the other structures that tended to leave the active site. Besides, there was a better understanding of the formation and stability of the existing H-bonds in the formed complexes and the energetic contributions to the stability of the target-ligand molecular complexes. Finally, the in silico prediction of the ADME profile suggested that LMed-136 has drug-like characteristics and good pharmacokinetic properties. Therefore, from the present study, it can be suggested that these structures can inhibit SARS-CoV-2 Mpro. Nevertheless, further studies are needed in vitro assays to investigate the antiviral properties of these structures against SARS-CoV-2. Graphical Abstract Communicated by Ramaswamy H. Sarma

1 January 2009 in Journal of the Brazilian Chemical Society
Verified
Journal Article
Open access
PDF file
LDLuiz C. Dias
Luiz C. Dias
TATatiana Augusto
Tatiana Augusto
CPCarla C. Perez
Carla C. Perez
LSLeonardo J. Steil
Leonardo J. Steil
Achiral and chiral allyltrichlorostannanes reacted with chiral ±-alkoxy aldehydes to give the corresponding homoallylic alcohols with moderate to good levels of 1,4-syn-diastereoselection.